Young David — SEC Form 4 filings
SEC reporting owner CIK 1378166. 18 Form 4 filings on record with FilingPulse; latest filed 2026-07-01.
Transaction summary — filings shown
Covers all 18 filings on record, filed 2024-02-07 to 2026-07-01. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 10 legs across 10 filings — 178,490 shares, $233,737 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 20.
- Largest priced transaction: purchase of 124,500 shares @ $0.80 ($99,289) in Processa Pharmaceuticals, Inc., filed 2025-01-29.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | Pres. Research & Development, Director | 18 | 10 legs · 178,490 sh · $233,737 | — | 20 |
Form 4 filings — Young David
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-01 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Purchase (P): 2,531 @ $1.93 | EDGAR |
| 2026-06-16 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Purchase (P): 2,067 @ $2.22 | EDGAR |
| 2026-06-01 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Purchase (P): 1,786 @ $2.57 | EDGAR |
| 2026-05-19 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Purchase (P): 1,545 @ $2.97 | EDGAR |
| 2026-05-01 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Purchase (P): 1,706 @ $2.69 | EDGAR |
| 2026-04-17 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Purchase (P): 1,545 @ $2.97 | EDGAR |
| 2026-04-01 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Purchase (P): 1,810 @ $2.54 | EDGAR |
| 2026-02-04 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Option exercise (M): 49 @ $0 · Option exercise (M): 49 (derivative) @ $0 | EDGAR |
| 2025-10-03 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Grant/award (A): 111,000 (derivative) @ $0 · Grant/award (A): 333,000 (derivative) @ $0 | EDGAR |
| 2025-09-18 | 4/A | Processa Pharmaceuticals, Inc. (PCSA) | Holdings only — no transactions reported | EDGAR |
| 2025-07-28 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Grant/award (A): 1,813,133 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Option exercise (M): 17,272 · Tax withholding (F): 5,345 @ $0.41 | EDGAR |
| 2025-02-18 | 4/A | Processa Pharmaceuticals, Inc. (PCSA) | Grant/award (A): 124,500 (derivative) @ $0 · Grant/award (A): 62,250 (derivative) @ $0 | EDGAR |
| 2025-01-29 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Purchase (P): 124,500 @ $0.80 | EDGAR |
| 2024-08-02 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Option exercise (M): 1,675 · Tax withholding (F): 518 @ $2.79 · Option exercise (M): 644 · Tax withholding (F): 282 @ $1.71 · Grant/award (A): 3,233 (derivative) @ $0 · Grant/award (A): 2,425 (derivative) @ $0 · +2 more | EDGAR |
| 2024-04-12 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Option exercise (M): 1,675 · Tax withholding (F): 518 @ $2.79 · Option exercise (M): 1,675 (derivative) @ $0 | EDGAR |
| 2024-02-08 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Purchase (P): 21,000 @ $2.45 | EDGAR |
| 2024-02-07 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Purchase (P): 20,000 @ $2.53 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1378166 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →